UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 30, 2012

ANACOR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

1020 East Meadow Circle

Palo Alto, CA 94303-4230

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (650) 543-7500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

On May 30, 2012, the Board of Directors (the “Board”) of Anacor Pharmaceuticals, Inc. (the “Company”) appointed Paul L. Berns to serve as a member of the Board as a Class III director with a term of office which expires at the Company’s 2013 annual meeting of stockholders.  Mr. Berns was simultaneously appointed to the Audit Committee of the Board.  Mr. Berns has served as the President and Chief Executive Officer, and as a member of the board of directors, of Allos Therapeutics, Inc. since March 2006.

Mr. Berns will receive compensation applicable to non-employee directors of the Company as follows:

·                  $25,000 annual cash retainer;

·                  $2,000 for each Board meeting attended in person and $1,000 for each Board meeting attended by telephone; and

·                  $1,500 for each Board committee meeting attended in person and $750 for each Board committee meeting attended by telephone.

On May 30, 2012, the Board also granted Mr. Berns an initial option to purchase 30,000 shares of the Company’s common stock (“Common Stock”) under the Company’s 2010 Equity Incentive Plan with an exercise price equal to $5.20, the fair market value of the Common Stock on the date of grant. Such initial option will vest in a series of three equal annual installments measured from the date of the grant.

At the Company’s 2012 annual meeting of stockholders held on May 30, 2012, the stockholders voted on the three proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the 2012 annual meeting, filed with the Securities and Exchange Commission on April 18, 2012 (the “Proxy Statement”).  The results of the matters voted upon at the meeting were:

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

3